Document Detail

Increased risk of rebleeding of peptic ulcer bleeding in patients with comorbid illness receiving omeprazole infusion.
MedLine Citation:
PMID:  14696515     Owner:  NLM     Status:  MEDLINE    
BACKGROUND/AIMS: The study aimed to evaluate whether administration of intravenous omeprazole has different rebleeding rates for peptic ulcer bleeding of patients with and without comorbid illness. METHODOLOGY: A total of 80 patients with peptic ulcer bleeding were enrolled after therapeutic endoscopy to achieve hemostasis. Each patient had received omeprazole 80 mg bolus loading and 40 mg twice daily for three days (total dosage of 320 mg within 3 days). Two subgroups were divided, based on the absence (Group A) or presence (Group B) of one or more comorbid illnesses, such as chronic obstructive pulmonary disease, congestive heart failure, uremia, cirrhosis, diabetes mellitus, and old stroke. The 7-day and 28-day rebleeding rates were recorded. RESULTS: The presence of comorbid illness had a higher rebleeding rate than those without comorbid illness (7-day: 32.5 vs. 2.5%, p < 0.05; 28-day: 37.5 vs. 5.0%, p < 0.05). Patients with two or more comorbid diseases had an even higher risk of rebleeding than those with a single comorbid illness (66.7% vs. 26.5%, p < 0.05). CONCLUSIONS: Low-dose infusion of omeprazole can achieve favorable control of rebleeding in the patients with peptic ulcer bleeding but without comorbid diseases. As patients with comorbid illness had a higher risk of rebleeding, a higher dosage or prolonged duration of omeprazole infusion would be rationally indicated to prevent risk of rebleeding.
Hsiu-Chi Cheng; Sam-An Chuang; Ya-Huey Kao; Ai-Wen Kao; Chiao-Hsiung Chuang; Bor-Shyang Sheu
Related Documents :
14696515 - Increased risk of rebleeding of peptic ulcer bleeding in patients with comorbid illness...
11824945 - Ulnar artery involvement in systemic sclerosis (scleroderma).
6740215 - Progression of antral and body gastritis in patients with active and healed duodenal ul...
11903245 - Lupus anticoagulant and venous leg ulceration.
7522685 - Soluble p-selectin in the plasma of patients with connective tissue diseases.
8888905 - Tinnitus maskers in the treatment of tinnitus. the microtek 321q.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Hepato-gastroenterology     Volume:  50     ISSN:  0172-6390     ISO Abbreviation:  Hepatogastroenterology     Publication Date:    2003 Nov-Dec
Date Detail:
Created Date:  2003-12-30     Completed Date:  2004-06-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8007849     Medline TA:  Hepatogastroenterology     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2270-3     Citation Subset:  IM    
Department of Internal Medicine, Institute of Clinical Medicine, National Cheng Kung University Hospital, 138, Sheng Li Road, Tainan, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Ulcer Agents / administration & dosage*
Dose-Response Relationship, Drug
Drug Administration Schedule
Hemostatic Techniques
Infusions, Intravenous
Liver Cirrhosis / epidemiology
Middle Aged
Omeprazole / administration & dosage*
Peptic Ulcer Hemorrhage / drug therapy*,  epidemiology*
Pulmonary Disease, Chronic Obstructive / epidemiology
Recurrence / prevention & control
Risk Factors
Treatment Failure
Uremia / epidemiology
Reg. No./Substance:
0/Anti-Ulcer Agents; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  How to eradicate Helicobacter pylori using amoxicillin and omeprazole in the remnant stomach.
Next Document:  High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. p...